YusriAliElsayedMDMHSc, PhD

PubMed

• 8 citations
  Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma.
  Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Baner...> ;Blood Advances. 2023 Feb 28
• Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
  Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W Hilder, Qun Jiao, Brett ...> ;Targeted Oncology. 2022 Sep 1
• 6 citations
  Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma.
  Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Arnob Banerjee, Tara Stephenson, Xuewen Ma, Shoba Shetty, Tong-Yuan Yang, Brandi W Hilder, Qun Jiao, Brett ...> ;Targeted Oncology. 2022 Jul 1
• 109 citations
  Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, s...
  Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San-Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin,...> ;Lancet. 2021 Aug 21
• 61 citations
  Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.
  Kodandaram Pillarisetti, Gordon Powers, Leopoldo Luistro, Alexander Babich, Baldwin Eric Thomas, Yingzhe Li, Xiaochun Zhang, Mark Mendonca, Nate Majewski, Rupesh Nanju...> ;Blood Advances. 2020 Sep 22
• 71 citations
  A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.
  Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonca, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen Walsh, Diana ...> ;Blood. 2020 Apr 9
• 27 citations
  A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
  Priyanka Nair-Gupta, Michael Diem, Dara Reeves, Weirong Wang, Robert Schulingkamp, Katrin Sproesser, Mattson Bethany Kay, Bradley Heidrich, Mark Mendonca, Jocelin Jose...> ;Blood Advances. 2020 Mar 10
• 41 citations
  Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
  F. Child, Pablo L. Ortiz-Romero, Rute Alvarez, Martine Bagot, Rudolf Stadler, Michael Weichenthal, R Alves, Pietro Quaglino, Marie Beylot-Barry, Richard A Cowan, Laris...> ;The British Journal of Dermatology. 2016 Jul 1
• 14 citations
  A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms
  William D. Figg, Manish Monga, Donna Headlee, Avni A. Shah, Cindy H. Chau, Cody J. Peer, Richard Messman, Yusri A. Elsayed, Anthony J. Murgo, Giovanni Melillo, Qin C. ...> ;Cancer Chemotherapy and Pharmacology. 2014 Sep 3
• 85 citations
  A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients...
  Balaji Venugopal, Richard D. Baird, Rebecca Kristeleit, Ruth Plummer, Richard A Cowan, Adam Stewart, Nele Fourneau, Peter Hellemans, Yusri Elsayed, Steve Mcclue, Johan...> ;Clinical Cancer Research. 2013 Aug 1
• 267 citations
  Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
  Kenneth J. Pienta, Jean-Pascal Machiels, D. Schrijvers, Boris Alekseev, Mikhail Shkolnik, Simon J. Crabb, Susan Li, Shobha Seetharam, Thomas A. Puchalski, C. H. Takimo...> ;Investigational New Drugs. 2013 Jun 1
• 14 citations
  Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab
  Bertrand Coiffier, Weimin Li, Henitz Erin Devay, Jayaprakash Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri Elsayed, Helgi van de Velde,...> ;Clinical Cancer Research. 2013 May 1
• 15 citations
  Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a ran...
  Pier Luigi Zinzani, Nuriet K. Khuageva, Huaqing Wang, Bernardo Garicochea, Jan Walewski, Achiel Van Hoof, Pierre Soubeyran, Dolores Caballero, Rena Buckstein, Dixie Le...> ;Journal of Hematology & Oncology. 2012 Oct 22
• 9 citations
  Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies
  Lia Gore, E. Rivera, Michele Basche, S. L. Moulder-Thompson, J. Li, S. Eppers, S. Grolnic, Cindy L. O'Bryant, D. Cleere, Y. A. Elsayed, S. G. Eckhardt> ;Investigational New Drugs. 2012 Oct 1
• 72 citations
  Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial
  Bertrand Coiffier, Osmanov Ea, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Jan Walewski, Sven de Vos, Michael Crump, Ofer S...> ;The Lancet. Oncology. 2011 Aug 1
• 34 citations
  Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects
  Simon W Dubrey, Donna E. Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean Paul Fermand, Robert Vescio, Joan Bladé, Leonard T. H...> ;QJM. 2011 Jul 13
• 49 citations
  Overall Survival: A Gold Standard in Search of a Surrogate: The Value of Progression-Free Survival and Time to Progression as End Points of Drug Efficacy
  Sen H. Zhuang, Liang Xiu, Yusri A. Elsayed> ;Cancer Journal. 2009 Sep 1
• 399 citations
  Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results ...
  George D. Demetri, Sant P. Chawla, Margaret von Mehren, Paul S. Ritch, Laurence H. Baker, Blay Jy, Kenneth R. Hande, Mary L. Keohan, Brian L. Samuels, Scott M. Schuetz...> ;Journal of Clinical Oncology. 2009 Sep 1
• 126 citations
  Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study.
  Donna E. Reece, Vaishali Sanchorawala, Ute Hegenbart, Giampaolo Merlini, Giovanni Palladini, Jean Paul Fermand, Robert Vescio, Xiangyang Liu, Yusri Elsayed, Andrew Cak...> ;Blood. 2009 Aug 20
• 63 citations
  Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
  Jean-Yves Blay, Margaret von Mehren, Brian L. Samuels, Michael P. Fanucchi, Isabelle Ray-Coquard, Brigid Buckley, Leen Gilles, Claudia Lebedinsky, Yusri A. Elsayed, Ax...> ;Clinical Cancer Research. 2008 Oct 15
• 26 citations
  Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors
  Wells A. Messersmith, Antonio Jimeno, David S. Ettinger, Daniel A. Laheru, Julie R. Brahmer, Dina Lansey, Yasmin Khan, Ross C. Donehower, Yusri Elsayed, Peter Zannikos...> ;Cancer Chemotherapy and Pharmacology. 2008 Apr 1
• 6 citations
  Procoagulant Properties of Atherosclerotic Aortasa
  Katsuo Sueishi, Kojiro Ichikawa, Kazunori Nakagawa, Kazuhiko Kato, Yusri Ali Elsayed, Masaaki Namoto> ;Annals of the New York Academy of Sciences. 2006 Dec 17
• Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies.
  Gore L, Rivera E, Lavallee K, Holden S, Grolnic S, Cleere D, Moulder SL, Elsayed YA, Eckhardt S> ;J. Clin. Oncol.. 2006-06-20
• Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies.
  Von Mehren M, Buck D, Temmer E, Elsayed YA, Cohen RB> ;J. Clin. Oncol.. 2006-06-20
• 93 citations
  Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-nec...
  Carter Van Waes, Angela A. Chang, Peter F. Lebowitz, Colleen H. Druzgal, Zhong Chen, Yusri A. Elsayed, John B. Sunwoo, Susan F. Rudy, John C. Morris, James B. Mitchell...> ;International Journal of Radiation Oncology, Biology, Physics. 2005 Dec 1
• Join now to see all